Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Also Known As
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies1000
Akcea Therapeutics
Akcea Therapeutics develops drugs for patients with serious cardiometabolic diseases caused by lipid disorders.
Sector
Subsector
Keywords
Location
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical develops therapeutics for rare and ultra-rare diseases.
Sector
Subsector
Location
total rounds
total raised
count Of Investments
LeadInvent Pharma
Invent Pharma is a nanomedicine company developing gel formulations for enhancing brain cancer surgery.
Sector
Subsector
Keywords
Location
Newron Pharmaceuticals
Newron Pharmaceuticals is developing novel therapies for diseases of the central nervous system and pain.
Sector
Subsector
Location
total rounds
total raised
Financials
Funding Rounds4
Number of Funding Rounds
Money Raised
Their latest funding was raised on 30.01.2024. Their latest investor Angelini Ventures. Their latest round Series A
Alpha Wave Ventures
Alpha Wave Ventures is an investment firm.
Sector
Subsector
Keywords
count Of Investments
Lumira Ventures
Lumira Ventures is a leading North American healthcare and life sciences venture capital firm.
Sector
Subsector
Location
count Of Investments
count Of Exists
Alpha Wave Ventures
Alpha Wave Ventures is an investment firm.
Sector
Subsector
Keywords
count Of Investments
Co-Investors
Investors7
Number of lead investors
Number of investors
Angelini Ventures
Angelini Ventures is an investment firm.
Sector
Subsector
Keywords
count Of Investments
Bristol Myers Squibb
Bristol-Myers Squibb is a pharmaceuticals and nutritional products company.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
count Of Exists
Alpha Wave Ventures
Alpha Wave Ventures is an investment firm.
Sector
Subsector
Keywords
count Of Investments
People
Founders2
John Puisis
John is a senior executive with over 25 years’ experience at transforming technology-based companies into product-based organizations. He combines a unique set of strategic, financial, talent management, and operating skills to identify unmet medical needs optimizing an organization to translate cutting–edge technology into products that address our most pressing hard to treat diseases to enhance people’s lives. Prior to co-founding and joining Cour, John was Co-Founder and CEO of Tolera Therapeutics. He led the company from initial startup through manufacturing optimization, pre-clinical, completion of a Phase 2 clinical trial, and filing of a Phase 3 Special Protocol Assessment (SPA) with the FDA. The company built significant barriers to entry by achieving several orphan drug designations and issuance of composition of matter patents utilizing a unique patent strategy. John was also instrumental to the startup of Cleveland Heart Labs (sold to LabCorp). He has served on the boards of Third Wave Technologies (NASDQ:TWTI) and ProNAi Therapeutics (NASDQ:DNAI), Tolera Therapeutics. John is a current board member at Cour Pharmaceuticals and advisory board member of NewCures of Northwestern University. He is also a member of the Economic Club of Chicago. Prior to Tolera, he was President and CEO of Third Wave Technologies (NASDAQ: TWTI), a biotechnology company, where he led the transformation of a non-sustainable genomics tools business into a robust growth-driven molecular diagnostics company primarily by leading the development of hard to detect infections and cancers. Third Wave was eventually sold for $600 million. John also served as a strategic consultant to DEKALB Genetics Corporation (NYSE) that was ultimately sold for $3.2 billion. Earlier in his career, John was with Spencer Stuart and Egon Zehnder International, in their life sciences practice groups where he consulted with biotech and pharmaceutical firms. After receiving his BS in Accounting from Northern Illinois University, John started his career at Arthur Andersen and also worked for Price Waterhouse. He received his MBA from the Kellogg School of Management at Northwestern University.
current job
organization founded
John Puisis
Jim Herrmann
Jim is a financial and operations executive with over 25 years experience spanning finance, product development, manufacturing and regulatory, in both diagnostics and therapeutics. Jim co-founded Tolera Therapeutics, where he worked with CEO John Puisis to raise $20 million and bring its MAb therapy from pre-clinical to a Phase 3 Special Protocol Assessment. Prior to this, Jim served as CFO for Third Wave Technologies (NASDAQ: TWTI), where he oversaw long-range and annual planning, company-wide systems and infrastructure development, operational management as well as quality system oversight. Jim oversaw the company’s first FDA 510k filing for a molecular diagnostic and the launch of its multiplexing diagnostic platform. Jim is a graduate of the University of Notre Dame and the University of Chicago (MBA).
current job
organization founded
Jim Herrmann
Employee Profiles4
Nicholas Bortolotti
Director, financial planning and analysis
John Puisis
Co-Founder, President and Chief Executive Officer
Activity
Recent News3
The graph reveals the ratio (%) of positive news articles in a chosen time range